Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Interim phase I results for SB-743921 reported at ASCO meeting
June 16th, 2005
Cytokinetics, Inc., (CYTK) announced that interim results from the phase I clinical trial of SB-743921 being conducted by GlaxoSmithKline (GSK) were presented in a poster session at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The presentation focused on the safety and tolerability of SB-743921, a small-molecule inhibitor of kinesin spindle protein, a mitotic kinesin essential for proper cell division. SB-743921 is the second drug candidate in clinical development arising from a broad strategic collaboration between Cytokinetics and GlaxoSmithKline to discover, develop, and commercialize...
Source: Women's Health Weekly (2005-06-16)
|
